Five things for pharma marketers to know: Monday, July 18, 2016

1. Roche said its blood cancer drug Gazyva did not significantly reduce the risk of disease or death for people with previously untreated diffuse large B-cell lymphoma. Roche also manufactures Rituxan, the drug against which Gazyva was compared. (Reuters)

2. The FDA said Valeant Pharmaceuticals' experimental psoriasis drug carries a potential risk of suicide. An FDA advisory committee is expected to meet this week to recommend whether the regulator should approve the therapy. (MedPage Today)

3. Facebook is testing a Snapchat-like feature that allows users of Messenger to send encrypted messages that disappear after as little as five seconds. (Adweek)

4. AbbVie and Amgen are seeking to deploy new patents to prevent the biosimilar arrivals of Humira and Enbrel, respectively. There are about 60 biosimilars in clinical trials, including 13 versions of Humira, which is used to treat arthritis, Crohn's disease, and others. Enbrel is a common treatment for plaque psoriasis and rheumatoid arthritis. (NYT)

5. AstraZeneca's experimental lung cancer drug Tagrisso met its main goal in a Phase-III clinical study. The drug was tested as a second-line treatment for certain lung cancers. (Reuters)